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ABSTRACT
Clinical pharmacogenomics (PGx) has the potential to make pharmacotherapy safer and more effective by utilizing
genetic patient data for drug dosing and selection. However, widespread adoption of PGx depends on its successful
integration into routine clinical care through clinical decision support tools, which is often hampered by insufficient
or fragmented infrastructures. This paper describes the setup and implementation of a unique multimodal, multilin-
gual clinical decision support intervention consisting of digital, paper-, and mobile-based tools that are deployed
across implementation sites in seven European countries participating in the Ubiquitous PGx (U-PGx) project.
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INTRODUCTION
Pharmacogenomics (PGx), i.e., using genetic data to guide drug-
dosing and selection, emerged as a promising strategy for making
pharmacotherapy safer and more effective.1–4 A successful imple-
mentation of PGx into clinical practice strongly depends on the
availability of clinical decision support (CDS) tools that translate
raw genetic test results into concise and clinically actionable thera-
peutic recommendations, and make those results available to health-
care providers at the point of care.5
Several projects utilizing different variants of PGx testing and
CDS have been launched; these projects are described and compared
in detail in Supplementary Material S1.6–23
A common factor of these successful PGx implementation proj-
ects is the delivery of CDS via the electronic health record (EHR), ei-
ther as an interruptive alert at the time of prescribing, or as part of
the patie’nt’s digital record. Although the availability of EHRs in
hospital settings significantly increased within the past decade and
reached adoption rates of >50% in most developed countries, na-
tionwide availability still cannot be expected in most regions.24,25
Moreover, a lack of interoperability between different existing EHR
systems as well as their fragmented availability beyond hospital set-
tings still constitute substantial barriers to the efficient and secure
sharing of PGx data.25–28
In this paper, we describe the development and implementation
of a unique, multi-modal, and multi-lingual PGx CDS strategy
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across 7 European countries in the context of the Ubiquitous PGx
(U-PGx) project that enables the delivery of PGx CDS in the pres-
ence of diverse and fragmented healthcare infrastructures.
IMPLEMENTING CDS IN THE U-PGx PROJECT
Project setting
Widespread adoption of PGx-guided prescribing in routine care will
heavily depend on the availability of robust data from large-scale
clinical studies that demonstrate improved clinical outcomes and
cost-effectiveness of PGx testing when applied to broad patient pop-
ulations. The Ubiquitous PGx (U-PGx) project was initiated to ad-
dress this need by implementing PGx panel testing and CDS across 7
European countries and measuring patient outcomes and cost-effec-
tiveness.29 The project started in January 2016 with a total duration
of 5 years and a budget of 15 million Euros from the Horizon 2020
EU research program.
The project includes a clinical study which was initiated in early
2017. It is designed as a prospective, block-randomized, controlled
study, and a total of 8100 patients are planned to be enrolled over
the course of three years (Clinicaltrials.gov NCT03093818). Patient
recruitment takes place at one or more healthcare institutions in
each of the 7 participating countries.
As part of the intervention, patients who receive a first prescrip-
tion of a drug, for which a pharmacogenomic guideline is available,
are tested for a panel of more than 48 clinically relevant PGx var-
iants across 13 important pharmacogenes relevant for dose optimi-
zation of 41 drugs.29 PGx testing is deployed in a mixed “reactive-
preemptive” approach, meaning that a full PGx panel is ordered at
the time of first prescription of a drug and dosage can be optimized
based on PGx guidelines. PGx panel results are then readily avail-
able for optimizing prescription of other drugs prescribed in future
interactions with the healthcare system.
Special requirements for the implementation of CDS in
the U-PGx project
The international setup of the U-PGx project entailed a special set of
demands that are unique among projects utilizing CDS for PGx.
While having to deal with heterogeneity (e.g., different types
of EHRs) is not uncommon in larger CDS implementation proj-
ects,30 this challenge is aggravated within the U-PGx project,
where technical framework conditions range from complete ab-
sence of any information technology (IT) infrastructure at some
implementation sites to sophisticated IT systems with the ability
to provide active CDS via automated alerts at others (see Table 1).
Furthermore, differences do not only exist between different par-
ticipating countries but also between participating sites within the
same country. Ensuring a standardized intervention while still
making optimal use of existing technical capabilities and meeting
essential country-specific requirements is therefore a key require-
ment in the U-PGx project.
Another fundamental challenge lies in maximizing the accessibil-
ity of PGx results within and between different healthcare settings.
Fragmented health IT infrastructures within countries and lacking
interoperability, as encountered in this project, entail a significant
risk of experiencing silo effects, meaning that information is trapped
in one system or institution and sharing between different systems
or institutions is impeded. Preemptive PGx testing is based on the ra-
tionale that testing patients for an entire panel of the most important
PGx variants at once may be cost-effective, because they will likely
profit several times from their PGx results in future interactions
with the healthcare system.31 Avoiding silo effects by ensuring the
accessibility and sharing of PGx results within and between different
healthcare settings, e.g., in- and outpatient settings, and healthcare
providers is therefore vital for a successful implementation of a pre-
emptive PGx strategy.
Besides these technical requirements, the international setting of
the project also poses unique challenges caused by the diversity of
languages and regulatory frameworks.
Devising a multi-modal CDS implementation strategy
To overcome challenges associated with implementing PGx CDS on
an international level and across multiple clinical sites with largely
diverging IT infrastructures, the U-PGx consortium has devised a
unique implementation strategy drawing from a spectrum of CDS
delivery modes deployed inside and outside of EHRs that
Table 1. Characteristics of Existing IT Infrastructures at the U-PGx Implementation Sites
Infrastructure characteristics NL GB IT ES AT SI GR
EHR inpatient setting Yes Yes Partially Yes Partially Partially No
EHR outpatient setting Yes Partially Partially Yes No No No
Text reports Yes Yes Yes Yes Yes Yes Yes





No Yes (for allergies) No No No
Passive CDS No Yes Yes Yes Yes No No
LIMS Yes Yes Yes Yes Yes Yes No
Structured laboratory results Yes Yes Yes Yes Yes No No
Abbreviations: AT, Austria; DDI, Drug-drug interactions; EHR, Electronic health record; ES, Spain; GB, Great Britain; GR, Greece; IT, Italy; LIMS, Labora-
tory information management system; NL, The Netherlands; PGx, Pharmacogenomics; SI, Slovenia.
Participating healthcare institutions as of August 2017: NL: A network of primary care physicians and pharmacies established by the department of Clinical
Pharmacy & Toxicology of the Leiden University Medical Center (LUMC); Department of Neurology, LUMC; Outpatient Pharmacy, LUMC. GB: The Royal Liv-
erpool University Hospital. IT: Medical Oncology and Radiotherapy Oncology Unit of the National Cancer Institute in Aviano and Treviso, Medical Oncology
and Radiotherapy Oncology Unit of the San Filippo Neri Hospital in Rome. ES: Departments of Pharmacy and Cardiology of the San Cecilio University Hospital
in Granada. AT: Department of Nephrology and Dialysis of the Vienna General Hospital. SI: Kidney transplant center, Nephrology Clinic, University Clinical
Center Ljubljana; Health Care Center Ljubljana, Health Care Center Kocevje, Health Care Center Litija; University Psychiatry Clinic Ljubljana.GR: Department
of Pharmacy, University of Patras; Psychiatric Clinic, Cardiology Clinic and Oncology Clinic of the General University Hospital in Patras.
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complement each other while still ensuring a standardized interven-
tion by using a centralized knowledge base (see Figure 1).
U-PGx knowledge base
Technical realization
For U-PGx, the curation of the knowledge base and the automated
translation of genetic data to associated phenotypes and recommenda-
tions are handled by the Genetic Information Management Suite
(GIMS), a Drupal-based content management system developed and
operated by the U-PGx partner bio.logis Genetic Information Manage-
ment GmbH.32,33 Using a web-based content management system for
knowledge base maintenance offers several advantages compared to us-
ing local or static solutions, such as a central workflow for editing,
translating, reviewing, and validating content and a transparent change
history across all participating sites (see Supplementary Material S2).
Content curation
The Dutch Pharmacogenetics Working Group (DPWG) is an ongoing
effort to develop concise and clinically actionable recommendations for
risk-phenotypes based on systematic literature review, and is formally
associated with U-PGx. Up to the time of this writing, the DPWG has
authored guidelines for 92 gene-drug pairs across 17 genes, all of which
are incorporated into the G-Standaard, a comprehensive Dutch drug
database, and regularly updated.29,34 This subset of the G-Standaard,
containing the PGx-based therapeutic recommendations, including the
data structure that links genotype-predicted phenotypes with active
ingredients and therapeutic recommendations was adopted unchanged
for the U-PGx knowledge base and is also available to interested parties
via an open-source license (see Supplementary Material S3).
Chemical substances and active ingredients are identified by their
Chemical Abstracts Service (CAS) number and the Anatomical Ther-
apeutic Chemical (ATC) Classification System code within the
knowledge base, respectively; a comprehensive systematic vocabu-
lary such as Systematized Nomenclature of Medicine – Clinical
Terms (SNOMED CT) is currently not utilized.35–37 An overview
and further description of the knowledge base data model is pro-
vided in Supplementary Material S4.
Based on the genotype variants included in the U-PGx panel,
rules for translating from genotypes to haplotypes and phenotypes
were curated by PGx experts in the project.
DPWG guidelines for clinically actionable phenotype-drug pairs
covered by the U-PGx genotyping panel were translated from Dutch
to the local languages of each participating country (English, Ger-
man, Greek, Slovenian, Spanish, and Italian) by certified translators
and validated by consortium members. Furthermore, representatives
from clinical implementation sites curated a list of the most common
local trade names for all drugs covered by the project. Phenotype
designations (e.g., “CYP2D6 ultrarapid metabolizer”) remained in
English to preserve a standardized designation across all implemen-
tation sites. For the initial phase of the project, the phenotype and
genotype terminology of the G-Standaard was adopted unchanged
(see Supplementary Material S3); efforts to standardize and harmo-
nize existing PGx terminologies and therapeutic recommendations
developed by different working groups are currently underway.38,39
Decision support tools
U-PGx GIMS does not only act as a centralized knowledge base in
the project but also serves as the main portal for the upload of ge-
netic data obtained from the U-PGx genotyping platform, and the
retrieval of patient-specific PGx reports in various formats. For this
purpose, GIMS offers a wide range of secure data transfer capabili-
ties, ranging from simple file (.csv) imports and uploads to modern
web-based application programming interface technologies, includ-
ing Hyper Text Transfer Protocol Secure (HTTPS)-based represen-
tation state transfer (RESTful) services and common standards like
Health Level Seven International (HL7) and Fast Healthcare Inter-
operability Resources (FHIR).40,41
As illustrated in Figure 2, U-PGx GIMS enables PGx CDS by the
following means: (1) the secure transfer of PGx test results and
patient-specific dosing recommendations in a structured format for
incorporation into local EHRs for use in passive or active CDS; (2)
the generation of a PGx report in Portable Document Format or
Open Document (ODT) format that can be filed either in the patient’s
digital or paper-based health record; and (3) the generation of a
“Safety-Code” card that enables mobile-based PGx CDS independent
of existing IT infrastructures (see Supplementary Material S2).
To conform to privacy and data security regulations, all data
that are exchanged between the implementation site and the central-
ized GIMS (i.e., PGx test results, PGx reports) are done with pseu-
donyms. Matching of PGx reports with identifying patient
information occurs locally at each implementation site.
PGx report
Delivering PGx CDS for an entire panel of PGx variants in a paper-
based form requires a careful report design to avoid overwhelming
clinicians. The U-PGx report was therefore structured to provide in-
formation most relevant at the point of care – such as for which
drugs a dosage adjustment is recommended for the respective patient
– right at the beginning of the report, whereas additional informa-
tion – such as the patients detailed PGx results – are provided on the
following pages (see Supplementary Material S2).
The report is generated by the GIMS Diagnostic Report Module,
which is certified as a medical device and holds the Conformite
Europeene (CE) mark in accordance with European legislation (EEC
93/42, EC 2007/47).
Safety-code card
To complement paper-based CDS solutions at clinical sites that lack
an EHR infrastructure and to maximize the accessibility and sharing
of PGx results within and between different healthcare settings and
healthcare professionals, the “Safety-Code” card system is deployed
at all participating institutions.42,43
Figure 1. Decision support solutions in U-PGx. The U-PGx CDS strategy com-
bines several complementary modes of delivering patient-specific PGx thera-
peutic recommendations to healthcare providers at the point of care, with or
without integration into local EHRs. Active, interruptive CDS alerts clinicians
of relevant gene-drug interactions via a pop-up message in the EHR or e-pre-
scription system at the time of prescribing. Passive CDS is delivered either in-
side the EHR system as a digital report, or outside the EHR system via
mobile- and paper-based solutions. The different decision support solutions
deployed in the U-PGx project including the underlying knowledgebase are
described in detail below.
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This card is part of a mobile clinical decision support (CDSS)
called the Medication Safety Code system which enables quick re-
trieval of patient-relevant PGx drug dosing guidelines even in the ab-
sence of a local EHR infrastructure.
Designed as a credit card-sized plastic card, the “Safety-Code”
card contains a quick response (QR) code that can be decoded and
interpreted by common smartphones and other devices (Figure 3).
After scanning the QR code, the medical professional is led to a
website that provides drug dosing recommendations customized to
the PGx profile of the patient.
Furthermore, the “Safety-Code” card contains an overview of
the patients’ most important PGx test results including a list of drugs
for which PGx-based dosing adjustments are recommended. Patients
participating in the PREemptive Pharmacogenomic testing for pre-
vention of Adverse drug Reactions (PREPARE) study are asked to
carry their “Safety-Code” cards with them and display them to med-
ical professionals when pharmacotherapy is initiated or altered,
which has the additional benefit of promoting patient engagement.
Card contents are generated through GIMS (see Supplementary
Material S2), and physical cards are printed locally at implementa-
tion sites with dedicated card printers.
The basic architecture of the Medication Safety Code system is
publicly available via an open-source license (see Supplementary
Material S3).
CDS implementation at clinical sites
Depending on their existing IT infrastructure and associated techni-
cal capabilities, each of the participating countries uses at least 2
complementary CDS methods for providing health care providers
with patient-specific PGx-based therapeutic recommendations
(Table 2). While main methods differ per country, all sites deploy
the “Safety-Code” card as an adjunct method to optimize informa-
tion diffusion within and between different healthcare providers.
Lessons learned
While a final reflection and assessment of our implementation
efforts can only be conducted after completion of the project, we
nevertheless want to share the most important experiences collected
over the course of this initial project phase.
Firstly, sufficient time should be ensured for the curation of the
knowledge base, and in particular, the curation of the mapping be-
tween the raw data output of the genotyping platform. In addition,
it is advisable to establish a workflow for dealing with rare variants
that may not be covered by the knowledge base. For U-PGx, such
variants are reported to a dedicated mailing list by implementation
site representatives, reviewed by experts in the consortium, and
added to the knowledge base.
Figure 2. Retrieval of PGx results and dosing recommendations for patients in the U-PGx project.
Figure 3. Front and back side of an exemplary Safety-Code card for a fictional
patient recruited in the U-PGx project
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Furthermore, the ability to quickly interpret and return partial
genotyping results should be considered. At early implementation
stages, some sites had problems with assays for 1 or 2 genes in the
panel, and requested the generation of PGx reports based solely on
the results of the remaining genes. This was not anticipated in the
initial design of the reporting software for pre-emptive PGx.
Finally, in case an integration into local EHR infrastructure is
envisaged, sufficient lead time should be scheduled for establishing
communication and collaboration with the local IT department and
dealing with often encountered bureaucratic obstacles, such as
obtaining necessary permits. This observation resonates with the
experiences reported earlier by Herr et al.30
DISCUSSION AND CONCLUSION
While automated alerts displayed via the EHR at the time of pre-
scribing are commonly viewed as the gold standard for delivering
CDS, their implementation is tied to the availability of an adequate
technical infrastructure which is currently still insufficient in many
healthcare settings.44,45 By developing and implementing a multi-
modal CDS concept, we demonstrate the feasibility of implementing
PGx CDS at multiple clinical sites across 7 countries in the presence
of largely fragmented and diverse health care infrastructures. We
use several complementary methods, including digital, paper-based,
and mobile CDS solutions that allow each participating institution
to choose their preferred combination of CDS tools that best fit their
institutional preferences and technical requirements.
As of June 2017, all CDS tools had been finalized and rolled out in
the countries that were randomized to start with the study arm, i.e.,
Greece, Slovenia, and Spain. Roll-out of CDS at sites that are currently
recruiting patients for the control arm (i.e., UK, the Netherlands, Aus-
tria, and Italy) will be commenced in summer 2018. The adoption and
usability of the different CDS tools deployed in the U-PGx project will
be evaluated at several time points throughout the study period; inter-
mediary results will be used for continuous improvement of the tools.
We hope that the project will successfully address the remaining
barriers to widespread adoption of PGx-guided prescribing and pre-
emptive testing strategies.
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